A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects

Healthy Volunteers Clinical Trial

Official title: A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects

Status Terminated

Clinical Trial Summary

To evaluate the effect of oral pH on the pharmacokinetics (PK) of a single oromucosal dose of Sativex (four sprays containing 10.8 mg Δ9 tetrahydrocannabinol (THC) and 10 mg cannabidiol (CBD)) by comparing the PK profile of Sativex in healthy subjects.

The primary clinical hypothesis is that there will be an effect of oral pH on the PK of Sativex when administered as a single oromucosal dose (four sprays).

Clinical Trial Description

This is a Phase I, randomised, open-label, three-way crossover study to assess the effects of oral pH on the PK of Sativex. Subjects will receive each of the following treatments in a random order across three residential treatment visits:

• Treatment A (acidic oral pH): Sativex (four sprays) after pre-treatment with Coca-Cola;

• Treatment B (neutral oral pH): Sativex (four sprays) after pre-treatment with tap water;

• Treatment C (alkaline oral pH): Sativex (four sprays) after pre-treatment with an oral suspension of magnesium hydroxide (milk of magnesia).

The target pH for each treatment will be determined from the results of a pilot study.

Each dose administration will be separated by at least seven days. Study subjects will participate in a total of five study visits. ;

Related Conditions & MeSH terms

• Healthy Volunteers

• NCT number: NCT02240160
• Study type: Interventional
• Source: GW Pharmaceuticals Ltd.
• Status: Terminated
• Phase: Phase 1
• Start date: August 2014
• Completion date: October 2015